LAVA Ebitda from 2010 to 2024

LVTX Stock  USD 1.60  0.05  3.23%   
LAVA Therapeutics EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA will likely drop to about -42.4 M in 2024. During the period from 2010 to 2024, LAVA Therapeutics EBITDA regression line of annual values had significance of  0.0006 and arithmetic mean of (17,694,596). View All Fundamentals
 
EBITDA  
First Reported
2018-12-31
Previous Quarter
-1.8 M
Current Value
-9.2 M
Quarterly Volatility
4.5 M
 
Covid
Check LAVA Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among LAVA Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 158.4 K, Net Interest Income of 3.1 M or Depreciation And Amortization of 1.3 M, as well as many indicators such as Price To Sales Ratio of 5.93, Dividend Yield of 0.0 or PTB Ratio of 0.78. LAVA financial statements analysis is a perfect complement when working with LAVA Therapeutics Valuation or Volatility modules.
  
Check out the analysis of LAVA Therapeutics Correlation against competitors.

Latest LAVA Therapeutics' Ebitda Growth Pattern

Below is the plot of the Ebitda of LAVA Therapeutics NV over the last few years. It is LAVA Therapeutics' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in LAVA Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

LAVA Ebitda Regression Statistics

Arithmetic Mean(17,694,596)
Coefficient Of Variation(78.39)
Mean Deviation11,566,462
Median(9,324,000)
Standard Deviation13,870,495
Sample Variance192.4T
Range34.5M
R-Value(0.78)
Mean Square Error80.2T
R-Squared0.61
Significance0.0006
Slope(2,428,529)
Total Sum of Squares2693.5T

LAVA Ebitda History

2024-42.4 M
2023-40.4 M
2022-30.9 M
2021-43.8 M
2020-14.7 M

About LAVA Therapeutics Financial Statements

LAVA Therapeutics investors use historical fundamental indicators, such as LAVA Therapeutics' Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in LAVA Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA-40.4 M-42.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for LAVA Stock Analysis

When running LAVA Therapeutics' price analysis, check to measure LAVA Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LAVA Therapeutics is operating at the current time. Most of LAVA Therapeutics' value examination focuses on studying past and present price action to predict the probability of LAVA Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LAVA Therapeutics' price. Additionally, you may evaluate how the addition of LAVA Therapeutics to your portfolios can decrease your overall portfolio volatility.